Navigation Links
Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
Date:10/8/2007

PALO ALTO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) announced today that Nathaniel M. Zilkha has been elected to the Company's Board of Directors, effective October 4, 2007. The Company also announced that Adam H. Clammer has resigned from its Board of Directors effective October 3, 2007.

Mr. Zilkha is a Principal at Kohlberg Kravis Roberts & Co. L.P., where he is a member of the Health Care industry team. Prior to joining KKR earlier this year, Mr. Zilkha was a Vice President in the Principal Investment Area of Goldman Sachs, where he executed and monitored private equity investments on behalf of the GS Capital Partners family of funds and led the group's efforts in Healthcare and Life Sciences. In his eight years in the Principal Investment Area, Mr. Zilkha was also involved with transactions across a range of other sectors, including energy, media, industrial and technology.

"We are very pleased to welcome Nat Zilkha to the Jazz Pharmaceuticals Board of Directors," said Bruce C. Cozadd, Executive Chairman of Jazz Pharmaceuticals. "On behalf of Jazz Pharmaceuticals' Board of Directors and management team, I thank Adam Clammer for his many contributions since joining our Board in February 2004."

About Jazz Pharmaceuticals, Inc. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.


'/>"/>
SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Tunnell ... joined the firm as senior statistician and Principal, a ... of experience in the management and analysis of complex ... and chemical industries. , “We’re delighted to have Julia ... in data analytics,” said Dr. Philippe Cini, Group Vice ...
(Date:5/20/2015)... , May 20, 2015 Research and Markets ... the "Top Technologies in HW_Technical Insights" report ... this report evaluated technology trends in the Health and ... are likely to have an impact in the year ... of the top 10 health and wellness technologies that ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) ... Therapy Market Outlook 2020 " report to their ... and regenerative medicine is expected to have huge marketing ... help in the growth of deregulated organs. Several therapeutic ... unable to form new tissue or sometimes organ transplant ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... 17 Arbel Medical, an Israeli,start-up developing the next ... has completed raising $4.5 million of,capital in its second ... The Docor International investment company, of the Van Leer ... who include Giza,Venture Capital, Ofer High Tech, the Bridge ...
... Stock Exchange Symbol: MS, EDMONTON, July 17 ... developer in the treatment of multiple sclerosis (MS), ... (DSMB) for the,Company,s phase II MINDSET-01 trial of ... a safety analysis and recommended,that the trial continue ...
... Raven,s Discovery Platform in Cancer Stem Cell Biology Enhances, ... ... Technology Platforms, ROCKVILLE, Md., July 17 ... treat,autoimmune disorders, cancer and infectious diseases, today announced the,acquisition of ...
Cached Biology Technology:Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund 2Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund 3BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2MacroGenics Acquires Raven Biotechnologies 2MacroGenics Acquires Raven Biotechnologies 3
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
(Date:5/7/2015)... , May 7, 2015 ... sensors, FPC1022 and FPC1035, FPC,s smallest touch fingerprint ... are mainly considered for integration on the backside ... smartphone OEMs increased possibilities to integrate touch fingerprint ... size also improves possibilities for module manufacturers to ...
(Date:4/27/2015)... FORT LAUDERDALE, Fla. , Apr. 27, 2015 /PRNewswire/ ... provider of access control and security systems is pleased ... joined the company as a consultant and member of ... Bedore is widely known as a thought leader ... Socrates Distance Learning Technology Group, and has published studies ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... young scholar, Fernando Rios loved science and computer programming ... degree in physics from Canada,s University of Waterloo ... Department of Scientific Computing at Florida State ... a new undergraduate program of computational sciences in fall ...
... VISALIA, Calif., July 6, 2011 EdeniQ, Inc. and ... subsidiary of the German firm IKA ® Werke ... agreement for the supply of biomass mixing and milling ... ongoing development of biomass milling process technologies. ...
... POF is not only associated with infertility but also ... decreased quality of life equivalent to that of people with ... from Imperial College, London, UK. Previous studies of POF, ... 40, have assessed the small group of women who seek ...
Cached Biology News:New software aids fight against nitrates in Florida's groundwater 2New software aids fight against nitrates in Florida's groundwater 3EdeniQ and IKA® Works Announce Global Partnership for Biomass Milling Technology 2EdeniQ and IKA® Works Announce Global Partnership for Biomass Milling Technology 3Socioeconomic class and smoking linked to premature menopause 2
5 minutes from gel band to purified DNA...
Collected from sexually matured, mixed breed, mixed sex guinea pigs....
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
Antibody specific for phosphorylattion of histone H3 that occurs during mitosis. Rabbit polyclonal serum. Antigen: Synthetic peptides derived from histone H3, phosphorylated at serines 10 or 28...
Biology Products: